Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

- PMLiVE

MS and cholesterol drugs picked for new UK rapid uptake push

Accelerated Access Collaborative aims to break down barriers to faster uptake

- PMLiVE

Novo Nordisk to launch connected insulin pens

Also partners with Dexcom, Glooko and Roche on digital platforms

Sanofi reception

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline

Dieter Weinand to be based in key US market

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Novo Nordisk and Evotec inks drug development deal

Will develop drugs for obesity and diabetes

- PMLiVE

Novo spends $800m to buy biotech and ‘glucose responsive insulin’ tech

Ziylo could help it stay ahead in key insulin franchise

- PMLiVE

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Firm relying on launch success in pressured US market

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

- PMLiVE

Ashfield and Sanofi scoop ICE award

Company wins the Most Effective Agency Collaboration Award for the second year running

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Research Partnership

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links